Regeneron Pharmaceuticals, Inc. (REGN)
Automate Your Wheel Strategy on REGN
With Tiblio's Option Bot, you can configure your own wheel strategy including REGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Published: March 04, 2026 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Read More
Why Dupixent Keeps Regeneron A Top Big Pharma Pick
Published: February 27, 2026 by: Seeking Alpha
Sentiment: Positive
Regeneron Pharmaceuticals ended 2025 and started this year on a high note. Regeneron and its partner Sanofi are among the leaders in the immune-mediated inflammatory diseases market. In Q4, Dupixent sales grew 22.8% year-on-year and 2.2% quarter-on-quarter to about €4.25 billion.
Read More
Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Published: February 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Read More
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
Published: February 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment
Read More
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
Published: February 24, 2026 by: GlobeNewsWire
Sentiment: Neutral
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo
Read More
Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Published: February 24, 2026 by: GlobeNewsWire
Sentiment: Neutral
Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the US to treat nine distinct diseases driven in part by type 2 inflammation, including sino-nasal, skin, gut …
Read More
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Negative
Regeneron foresees further Eylea decline in 2026 as biosimilars loom, but Eylea HD, Dupixent and Libtayo aim to steady revenues.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
Published: January 30, 2026 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
Read More
Regeneron bets added cholesterol benefit will help its obesity drug stand out
Published: January 30, 2026 by: Reuters
Sentiment: Positive
Regeneron Pharmaceuticals' executives voiced confidence in its experimental weight-loss drug on Friday, saying added cholesterol-lowering benefits could give the company an edge in an increasingly crowded obesity market.
Read More
Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
REGN beats Q4 earnings estimates as Eylea HD and Dupixent profits lift revenues, though higher expenses drive a year-over-year EPS decline.
Read More
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings?
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
REGN's Q4 report could hinge on Dupixent profit growth and strong Eylea HD uptake as legacy Eylea sales face competitive pressure.
Read More
Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026
Published: January 23, 2026 by: Seeking Alpha
Sentiment: Positive
Regeneron Pharmaceuticals, Inc. is approaching a pivotal earnings report following a strong JP Morgan Healthcare Conference update. I maintain a Buy rating on REGN, supported by a >16% share price gain since my last note. Despite recent gains, REGN trades well below its ~$1,200 all-time high from August 2024.
Read More
REGN or ILMN: Which Is the Better Value Stock Right Now?
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
Published: January 21, 2026 by: GlobeNewsWire
Sentiment: Neutral
Society for Science & Regeneron announced the finalists in the Regeneron Science Talent Search, the nation's oldest and most prestigious STEM competition
Read More
Regeneron (REGN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Regeneron (REGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Regeneron Pharmaceuticals upgraded by Bank of America on improving fundamentals, 2026 catalysts
Published: January 07, 2026 by: Proactive Investors
Sentiment: Positive
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been upgraded by Bank of America, which raised its rating on the biotechnology company to ‘Buy' from ‘Underperform' and increased its price objective to $860 from $627, citing improving fundamentals across key products and multiple potential catalysts in 2026. Shares of Regeneron traded up 3.5% at about $803 on Wednesday afternoon.
Read More
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
REGN vs. ILMN: Which Stock Is the Better Value Option?
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
REGN vs. ILMN: Which Stock Should Value Investors Buy Now?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
Published: January 02, 2026 by: Zacks Investment Research
Sentiment: Positive
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
Read More
Regeneron (REGN) Just Flashed Golden Cross Signal: Do You Buy?
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Regeneron (REGN) is looking like an interesting pick, as it just reached a key level of support. REGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Read More
Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv
Published: December 10, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript
Published: December 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript
Read More
Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
Published: December 10, 2025 by: Reuters
Sentiment: Positive
A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow transplants, preliminary data from a small mid-stage trial suggest.
Read More
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
Published: December 08, 2025 by: Seeking Alpha
Sentiment: Positive
Regeneron Pharmaceuticals once again beat consensus EPS and revenue estimates by a wide margin. Moreover, as of September 30, Regeneron had about $2.2 billion remaining under its authorized share repurchase program, underscoring its ongoing efforts to create long-term value for its investors. However, I believe the European Commission's approval of Dupixent for the treatment of chronic spontaneous urticaria on November 25 is even more important.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Read More
About Regeneron Pharmaceuticals, Inc. (REGN)
- IPO Date 1991-04-02
- Website https://www.regeneron.com
- Industry Biotechnology
- CEO Leonard S. Schleifer
- Employees 15158